Blueprint Medicines Retained Earnings (Accumulated Deficit) 2014-2024 | BPMC

Blueprint Medicines retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-2.357B, a 5.74% increase year-over-year.

  • Blueprint Medicines retained earnings (accumulated deficit) for 2023 were $-2.34B, a 27.66% increase from 2022.
  • Blueprint Medicines retained earnings (accumulated deficit) for 2022 were $-1.833B, a 43.71% increase from 2021.
  • Blueprint Medicines retained earnings (accumulated deficit) for 2021 were $-1.275B, a 102.02% increase from 2020.

Blueprint Medicines Retained Earnings (Accumulated Deficit) 2014-2024 | BPMC

  • Blueprint Medicines retained earnings (accumulated deficit) for 2023 were $-2.34B, a 27.66% increase from 2022.
  • Blueprint Medicines retained earnings (accumulated deficit) for 2022 were $-1.833B, a 43.71% increase from 2021.
  • Blueprint Medicines retained earnings (accumulated deficit) for 2021 were $-1.275B, a 102.02% increase from 2020.